Telomir Pharmaceuticals (TELO) Projected to Announce Earnings on Wednesday

Posted by Brian Himes on Aug 31st, 2026

Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) will likely be issuing its results after the market closes on Wednesday, September 2nd. Analysts expect Telomir Pharmaceuticals to announce earnings of ($0.07) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.72).

Telomir Pharmaceuticals Price Performance

Shares of NASDAQ:TELO opened at $1.14 on Monday. Telomir Pharmaceuticals has a fifty-two week low of $0.89 and a fifty-two week high of $2.09. The firm’s 50 day moving average price is $1.18 and its 200 day moving average price is $1.25. The stock has a market cap of $78.41 million, a price-to-earnings ratio of -1.25 and a beta of -0.24.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TELO. Bank of America Corp DE boosted its holdings in Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after purchasing an additional 10,880 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in Telomir Pharmaceuticals during the second quarter worth approximately $33,000. Geode Capital Management LLC raised its holdings in Telomir Pharmaceuticals by 14.0% during the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock worth $297,000 after purchasing an additional 27,519 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Telomir Pharmaceuticals during the 4th quarter worth approximately $53,000. Finally, Jane Street Group LLC acquired a new position in shares of Telomir Pharmaceuticals in the 2nd quarter valued at $62,000.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Read Our Latest Stock Report on Telomir Pharmaceuticals

About Telomir Pharmaceuticals

(Get Free Report)

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.